Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients

Heart Failure Clinical Trial

— CRT-LVAD  

Official title:

Cardiac Resynchronization Therapy in Patients With Left Ventricular Assist Devices

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02169076
• Other study ID #: 14.0338
• Status: Withdrawn
• Phase: N/A
• First received: June 18, 2014
• Last updated: January 3, 2017
• Start date: September 2014
• Est. completion date: May 2016

Study information

• Verified date: January 2017
• Source: University of Louisville
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Left Ventricular Assist Devices (LVAD) are mechanical heart pumps that are increasingly being implanted in patients with severe heart failure which have failed medical therapy. In patients with LVADs, right ventricular failure, which is not supported by the LVAD pump, is a major problem that affects quality-of-life and survival. Cardiac Resynchronization Therapy (CRT) aims to restore the synchronized contraction of the heart and has proven to be beneficial for improving ejection fraction of both right and left ventricle as well as quality of life in selected heart failure patients. The role of CRT in patients with LVADs is unknown. We hypothesize that CRT can exert a beneficial impact on right ventricular function in LVAD patients and improve their quality-of-life.

The specific questions that this study aims to answer are:

1. What are the effects of CRT on the function of the non-supported right ventricle in patients with an implanted LVAD?

2. Can the effects of CRT on cardiac function positively impact quality-of-life and exercise capacity in LVAD recipients?

In this study patients with a previously implanted CRT device, who later receives an LVAD, will be randomly assigned to have the CRT turned off (CRT-off) or on (CRT-on). The patients will be followed for an 8-week period, and then switched over to the opposite CRT status. The total participation in this study will last for 16 ± 1 weeks, and will involve 3 clinic visits of approximately 3 hour duration (initial visit, 8 week visit, and 16 week final visit), plus 2 quick checks of the pacemaker/defibrillator in-between the visits. Heart function will be assessed with comprehensive echocardiographic studies during the CRT "on" and CRT "off" periods. Quality-of-life and exercise capacity will be assessed with a standardized questionnaire and a 6-Minute Walk Test.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2016
• Est. primary completion date: May 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Heart failure patients with previously implanted Bi-Ventricular pacemaker / defibrillator, and continuous flow LVAD (Heart Mate II® or HeartWare®)

• The LVAD must be implanted between 8 weeks and 18 months prior to enrollment

• Patients should be at least 3 weeks post discharge from the LVAD implant hospitalization

Exclusion Criteria:

• Severe decompensated right ventricular failure defined as requiring any of the following:

• Hospitalization for heart failure within last 30 days

• Need for inotropic infusion for > 48h within the last 14 days

• Increase of > 100% diuretic dose within last 14 days

• Severe aortic regurgitation documented by echocardiography or cardiac catheterization

• Stage IV or greater kidney disease (GFR < 30 mL/min/1.73 m2)

• Active infection (not including controlled chronic driveline infection on suppressive antibiotic therapy)

• Biventricular pacing < 90 % of time due to uncontrolled arrhythmias

• LVAD malfunction

• Inability to follow study protocol

• Non-functional LV lead (i.e. high capture threshold that cannot be corrected with programming changes)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Heart Failure

Intervention

Device:
• Cardiac Resynchronization Therapy
The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.

Locations

Country	Name	City	State
United States	Jewish Hospital	Louisville	Kentucky

Sponsors (1)

Lead Sponsor	Collaborator
University of Louisville

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quality-of-Life	Assessed by standardized self administered Minnesota Living with Heart Failure Questionnaire (MLHFQ)	8 weeks	No
Primary	Right ventricular function	The primary cardiac performance endpoint is global longitudinal right ventricular (RV) function assessed by myocardial strain analysis using Speckle Tracking Echocardiography (STE).; Other traditional echocardiographic RV function indexes will also be evaluated.	8 weeks	No
Secondary	Functional capacity	Will be assessed by 6-Minute Walk Test	8 weeks	No